Pharma/Biotech News
Subscribe to Pharma/Biotech News

The Lead

Breaking News: Cubist Recalls Cubicin Lot

April 18, 2014 2:02 pm | News | Comments

Cubist Pharmaceuticals Inc. announced it is voluntarily recalling one lot of Cubicin (daptomycin for injection) to the user level due to the presence of particulate matter, reported via customer complaint and identified as glass particles. Read more...

Top French Advisor Resigns Amid Drug Industry Scandal

April 18, 2014 1:06 pm | News | Comments

Aquilino Morelle, the French president's top adviser...

Washington University Launches Immunology Center

April 18, 2014 12:54 pm | by Michael Purdy | News | Comments

A new center at Washington University School of Medicine in St. Louis - ...

New Pain Relief Targets Could Benefit Cancer Patients

April 18, 2014 12:36 pm | News | Comments

When researching how pain occurs in nerves in the periphery...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Phase 1/2 Results Positive for Cancer Drug

April 18, 2014 12:20 pm | News | Comments

XBiotech is announcing that results from its Phase 1/2 oncology study conducted at MD Anderson Cancer Center in Houston, TX were published in Lancet Oncology, which describes the outcome in 52 advanced cancer patients treated with Xilonix, XBiotech’s anti-tumor therapy. Read more...

Ivabradine Fast Tracked for Chronic HF

April 18, 2014 12:13 pm | News | Comments

The U.S. Food and Drug Administration (FDA) has granted fast track designation for investigational ivabradine - an oral drug that inhibits the If current (“funny” current) in the sinoatrial node, the body’s cardiac pacemaker - for patients with chronic heart failure (HF). Read more...

FDA Approves Arzerra for Chronic Lymphocytic Leukemia

April 18, 2014 12:03 pm | News | Comments

GlaxoSmithKline and Genmab announced that the FDA has approved a supplemental BLA for the use of Arzerra, a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia. Read more...


Actavis to Acquire New Products from Akorn

April 18, 2014 10:19 am | News | Comments

Actavis plc announced that it has entered into agreements with Akorn Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. Read more...         

Multi-Target TB Drug May Treat Other Diseases, Evade Resistance

April 18, 2014 9:53 am | News | Comments

A drug under clinical trials to treat tuberculosis could be the basis for a class of broad-spectrum drugs that act against various bacteria, fungal infections and parasites, yet evade resistance, according to a new study. Read more...     

Canada is First to Approve GSK's New COPD Drug

April 18, 2014 9:43 am | News | Comments

GlaxoSmithKline announced that Incruse Ellipta has received world-first market authorization in Canada for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD. Read more...       

Canada is First to Approve GSK's New COPD Drug

April 18, 2014 9:43 am | News | Comments

GlaxoSmithKline announced that Incruse Ellipta has received world-first market authorization in Canada for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD. Read more...       

Servier, Lab Founder in Drug Scandal, Dies at 92

April 18, 2014 9:17 am | News | Comments

Jacques Servier, the founder of France's second-largest pharmaceutical group who became ensnared in a scandal over a diabetes drug widely used for weight loss, has died. Read more...                   


FDA OKs Merck Tablet to Reduce Ragweed Allergies

April 18, 2014 9:00 am | News | Comments

U.S. regulators have again approved Merck & Co.'s Ragwitek tablets, which dissolve quickly under the tongue, for gradually reducing seasonal allergies, this time for ragweed pollen. Read more...             

NIH Awards Scripps $2M to Design a Better Diabetes Drug Model

April 17, 2014 1:21 pm | News | Comments

Scientists from the Florida campus of TSRI have been awarded $2.1 million from the NIH to study the therapeutic potential of safer and more effective alternatives to the current crop of anti-diabetic drugs, which have been limited in their use due to side effects including bone loss and CHF. Read more...

Finding Suggests New Possibilities for Oncology and Virology

April 17, 2014 1:06 pm | News | Comments

Scientists at Washington University School of Medicine in St. Louis have uncovered a new way the immune system may fight cancers and viral infections, which could aid efforts to use immune cells to treat illness. Read more...     

Sanguine, Mayo Clinic Agreement Furthers Personalized Medicine

April 17, 2014 12:40 pm | News | Comments

Sanguine announced an agreement with Mayo Clinic Bioservices, under which Mayo Clinic Bioservices will process, store and ship biospecimens that Sanguine has collected. Read more...                   

VentiRx Completes Enrollment in Study of Orphan Cancer Drug

April 17, 2014 11:47 am | News | Comments

VentiRx Pharmaceuticals Inc. announced that enrollment has been completed in a Phase 2 trial of VTX-2337 in combination with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior platinum-based chemotherapy. Read more...


GSK Reports More Bribery Inquiries

April 17, 2014 11:24 am | News | Comments

British drugmaker GlaxoSmithKline is looking into allegations of bribery within its operations in Jordan and Lebanon. The company is also facing a corruption investigation in China and a bribery investigation in Poland and is looking into alleged bribery in Iraq. Read more...

'Matrix' Trial Will Advance Personalized Medicine for Lung Cancers

April 17, 2014 10:52 am | Videos | Comments

The "National Lung Matrix" trial, a partnership between Cancer Research UK, AstraZeneca and Pfizer, will give researchers unprecedented access to libraries of drugs developed by the companies, allowing several to be tested at the same time, within one trial. Read more...

Cancer Drugs Block Dementia-Linked Brain Inflammation

April 17, 2014 10:40 am | News | Comments

A class of drugs developed to treat immune-related conditions and cancer– including one currently in clinical trials- eliminates neural inflammation associated with dementia-linked diseases and brain injuries, according to researchers. Read more...

EC, FDA Give Orphan Status to Boehringer’s New Leukemia Drug

April 17, 2014 10:36 am | News | Comments

Boehringer Ingelheim Pharmaceuticals announced that the FDA and European Commission have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML). Read more...                   

Astellas to Pay $7.3M in Mycamine Marketing Settlement

April 17, 2014 10:13 am | News | Comments

A unit of Japanese drugmaker Astellas Pharma will pay the U.S. government $7.3 million to resolve claims it illegally marketed its antifungal drug Mycamine for children before that use was approved. Read more...            

Phase 1 Results Positive for Tumor Vaccine

April 16, 2014 2:00 pm | News | Comments

Celldex Therapeutics Inc. announced that final data from its Phase 1 study of CDX-1401 (an off-the-shelf vaccine that targets dendritic cells) in solid tumors, including long-term patient follow-up, have been published in Science Translational Medicine. Read more...

HPV Vaccine Works in HIV+ Women

April 16, 2014 2:00 pm | News | Comments

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial, countering doubts about whether the vaccine would be helpful. Read more...

Measles Drug Lowers Viral Load

April 16, 2014 2:00 pm | News | Comments

A novel antiviral drug may protect people infected with the measles from getting sick and prevent them from spreading the virus to others, an international team of researchers said. Read more...                  

Small Molecule Shows Potential in Advanced Cancers

April 16, 2014 1:34 pm | News | Comments

Cleveland BioLabs Inc. announced the achievement of all objectives in a Phase 1 clinical trial of CBL0102, or quinacrine, an orally administered small molecule in patients with advanced cancers for which no standard care exists or which had become resistant to conventional therapies. Read more...

Baxter's Orphan Drug Candidate Hits Key Phase 3 Endpoint

April 16, 2014 1:06 pm | News | Comments

Baxter International Inc. announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics of BAX 111, a recombinant von Willebrand factor under investigation for the treatment of bleeding episodes in patients with von Willebrand disease. Read more...

Recall Hurts Abbott, But Q1 Expectations Topped

April 16, 2014 1:00 pm | News | Comments

Abbott Laboratories' first-quarter net income tumbled 31% on unfavorable currency exchanges and a supplier recall that lowered sales of its baby formula, but the company beat most expectations and shares edged higher in early trading Wednesday. Read more...

3-D Printed Tissues May Aid Drug Delivery, Wound Healing

April 16, 2014 11:13 am | News | Comments

A University of Oxford spin-out, OxSyBio, will develop 3-D printing techniques to produce tissue-like synthetic materials for wound healing and drug delivery. Read more...                       

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.